매크로제닉스 (MGNX) 주가

매크로제닉스(MGNX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $4.16 (+0.73%), 시가총액 $0.27B, 52주 최저~최고 $1.19 ~ $4.25.

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC)

핵심 지표

• 현재가: $4.16 (+0.73%)
• 시가총액: $0.27B
• 52주 최저~최고: $1.19 ~ $4.25
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

매크로제닉스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

매크로제닉스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 3.5556

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 3.44
• 순이익률: -0.45%
• 영업이익률: -1.61%

자주 묻는 질문